Clinical trial
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
NCT02635776 is registered in ClinicalTrials.gov with Aimmune Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
- Lead sponsor
- Aimmune Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 22, 2015
- Completion date
- July 2, 2018
- Enrollment
- 555 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.
peanut allergy